secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001493152-22-012876
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals appoints Robert Chen as CFO effective May 16, 2022, replacing Marc Bregman
--------------------------------------------------------------------------------

- Robert Chen named CFO; base salary $250,000/year; at-will employment starting May 16, 2022.
- Chen receives stock options for 900,000 shares, vesting over 3 years from issuance.
- Prior CFO Marc Bregman ceased services as Secretary and Treasurer effective April 29, 2022.
- Chen brings 20+ years life science finance experience, most recently VP Finance at KBP Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/0001493152-22-012876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer